Quota Marketplace: Dynamic Pricing for Efficient Allocation of ML Training Resources

The escalating demand for Machine Learning (ML) training resources in recent years has resulted in a substantial gap between the high demand and the available supply. Efficient allocation of these scarce and expensive resources is crucial for organizations to maximize their return on investment. Existing resource allocation mechanisms, like Karma [OSDI'23], are designed to guarantee Pareto efficiency and max-min fairness in settings with dynamic (time-varying) user demands, but fail to preserve these key properties in the presence of demands with heterogeneous values. Given the ubiquity and inevitability of heterogeneity in organizational values of different workloads, effective resource allocation policies must accommodate these variations. In this paper, we describe the design, implementation, deployment, and theoretical analysis of Quota Marketplace, a market-based mechanism to efficiently allocate ML training chips (like GPUs), explicitly addressing scenarios with demands of heterogeneous value. We detail the implementation of this mechanism within Google and present metrics that demonstrate its impact. We also discuss many business-critical requirements that the Quota Marketplace handles quite effectively, and document the gains and opportunities it has unlocked. We establish theoretically how this market-based approach achieves the essential properties of Pareto efficiency and max-min fairness by allowing the users to express the value of their workloads and enabling dynamic resource pricing based on supply and demand fluctuations. Ultimately, the market facilitates resource allocation that aligns with organizational priorities.

Towards an AI co-scientist

Scientific discovery relies on scientists generating novel hypotheses that undergo rigorous experimental validation. To augment this process, we introduce an AI co-scientist, a multi-agent system built on Gemini 2.0. The AI co-scientist is intended to help uncover new, original knowledge and to formulate demonstrably novel research hypotheses and proposals, building upon prior evidence and aligned to scientist-provided research objectives and guidance. The system's design incorporates a generate, debate, and evolve approach to hypothesis generation, inspired by the scientific method and accelerated by scaling test-time compute. Key contributions include: (1) a multi-agent architecture with an asynchronous task execution framework for flexible compute scaling; (2) a tournament evolution process for self-improving hypotheses generation. Automated evaluations show continued benefits of test-time compute, improving hypothesis quality. While general purpose, we focus development and validation in three biomedical areas: drug repurposing, novel target discovery, and explaining mechanisms of bacterial evolution and anti-microbial resistance. For drug repurposing, the system proposes candidates with promising validation findings, including candidates for acute myeloid leukemia that show tumor inhibition in vitro at clinically applicable concentrations. For novel target discovery, the AI co-scientist proposed new epigenetic targets for liver fibrosis, validated by anti-fibrotic activity and liver cell regeneration in human hepatic organoids. Finally, the AI co-scientist recapitulated unpublished experimental results via a parallel in silico discovery of a novel gene transfer mechanism in bacterial evolution. These results, detailed in separate, co-timed reports, demonstrate the potential to augment biomedical and scientific discovery and usher an era of AI empowered scientists.